GLOBAL HEALTH | GLOBAL PARTNERSHIPS | GLOBAL IMPACT

Research

Photo for STRIVE

STRIVE

Official Title

Adjunctive, low-dose intracoronary recombinant tissue plasminogen activator (tPA) versus placebo for primary PCI in patients with ST-segment elevation myocardial infarction.

Status

Ongoing

Overview

STRIVE will evaluate the use of adjunctive, low-dose intracoronary tissue plasminogen activator during primary percutaneous coronary intervention (PCI) for patients with ST elevation myocardial infarction (STEMI) in reducing major adverse cardiovascular events. STRIVE will assess the efficacy of a novel approach to prevent and treat microvascular obstruction and reduce major cardiovascular events using intracoronary administration of very low-dose fibrinolytic (tissue plasminogen activator, tPA) directly into the culprit coronary artery during primary PCI.

The objective is to determine if low-dose adjunctive intracoronary tPA (10 mg or 20 mg) will reduce the incidence of post-procedural myocardial blush (MBG) grade 0/1 or distal embolization in patients undergoing primary PCI for STEMI.

Study Design

Prospective, 3-arm, parallel group, open label, randomized controlled trial

Primary Endpoint

Composite of post-procedural myocardial blush (MBG) grade 0/1 or distal embolization.

Number of Patients

200

Number of Sites

4

Number of Countries

1

Study Period

2018-2019

Principal Investigator

Shamir Mehta

Program Manager

Brandi Meeks

Research Coordinator

Sabine Brett

For more information, please visit https://clinicaltrials.gov/ct2/show/NCT03335839

Follow by Email
LinkedIn
Twitter
FACEBOOK